The success of copyright’s blockbuster initially sparked a boom for major pharmaceutical companies, however recent shifts present a uncertain outlook for investors. Off-patent competitors are eroding profits, and ongoing litigation add further risk to the situation. While some companies might still see gains from complementary offerings, the gene